CRNP CRNP - Panbela Therapeutics Pres CEO
| PBLADelisted Stock | USD 2.06 0.11 5.07% |
Insider
CRNP CRNP is Pres CEO of Panbela Therapeutics
| Age | 54 |
| Phone | 952 479 1196 |
| Web | https://www.panbela.com |
Panbela Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.9187) % which means that it has lost $1.9187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.9816) %, meaning that it created substantial loss on money invested by shareholders. Panbela Therapeutics' management efficiency ratios could be used to measure how well Panbela Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Panbela Therapeutics currently holds 6.84 M in liabilities. Panbela Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Panbela Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Robert McRae | Palisade Bio | N/A | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| John CPA | Unicycive Therapeutics | 62 | |
| Chester III | Revelation Biosciences | 44 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
Management Performance
| Return On Equity | -7.98 | ||||
| Return On Asset | -1.92 |
Panbela Therapeutics Leadership Team
Elected by the shareholders, the Panbela Therapeutics' board of directors comprises two types of representatives: Panbela Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Panbela. The board's role is to monitor Panbela Therapeutics' management team and ensure that shareholders' interests are well served. Panbela Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Panbela Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CRNP CRNP, Pres CEO | ||
| CRNP MSN, President CEO | ||
| Susan Horvath, CFO, Finance | ||
| Tammy Groene, Vice Operations | ||
| Elizabeth Bruckheimer, VP Officer |
Panbela Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Panbela Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.98 | ||||
| Return On Asset | -1.92 | ||||
| Current Valuation | 8.64 M | ||||
| Shares Outstanding | 3.48 M | ||||
| Shares Owned By Institutions | 0.59 % | ||||
| Number Of Shares Shorted | 106.97 K | ||||
| Price To Book | 3.22 X | ||||
| EBITDA | (34.76 M) | ||||
| Net Income | (34.93 M) | ||||
| Cash And Equivalents | 2.53 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Panbela Stock
If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |